Comment on Herring et al. The Use of "Retardation" in FRAXA, FMRP, FMR1 and Other Designations.

Elspeth Bruford, On Behalf Of The Hugo Gene Nomenclature Committee Hgnc

Abstract readComment

In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Directly reprogrammed fragile X syndrome dorsal forebrain precursor cells generate cortical neurons exhibiting impaired neuronal maturation.Frontiers in cellular neuroscience · 2023
Article
The importance of being the HGNC.Human genomics · 2022
Review
FMRP, a multifunctional RNA-binding protein in quest of a new identity.Frontiers in genetics · 2022
Article

4 · The record

Corrections and comments

Comment on
The Use of "Retardation" in FRAXA, FMRP, FMR1 and Other Designations.2022

5 · Who and what money

Authors and funding

2 authors.

Elspeth BrufordDepartment of Haematology, University of Cambridge School of Clinical Medicine, Cambridge CB2 0PT, UK.ORCID 0000-0002-8380-5247

On Behalf Of The Hugo Gene Nomenclature Committee HgncHUGO Gene Nomenclature Committee, EMBL-EBI, European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton CB10 1SD, UK.

Funding

The Nomenclature of Human and Vertebrate GenesU24HG003345 · NHGRI · UNIVERSITY OF CAMBRIDGE · PI Elspeth Bruford · 2018 to 2026

$3.9M

NHGRI NIH HHS U24 HG003345Wellcome TrustWellcome Trust 208349/Z/17/Z

6 · The paper itself

Abstract

This commentary is written in response to the recent article from Herring et al., discussing the eradication of the offensive term "retardation" from gene nomenclature. We discuss the work of the HUGO (Human Genome Organisation) Gene Nomenclature Committee (HGNC) and outline the steps already taken to remove this term from our gene names. We also highlight the latest nomenclature changes made as a result of discussions with the authors and agreement with the European Fragile X Network.

Indexed as

Fragile X Messenger Ribonucleoprotein 1Fragile X SyndromeHumansFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1FMR1fragile X syndromeFRAXAgene nomenclatureHGNC

Identifiers

PMID35741066

DOI10.3390/cells11121937

PMCPMC9221639

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.